Health Care
Pro Medicus Limited (PME)
Pro Medicus Limited (PME) is an Australian health care technology company focused on diagnostic imaging solutions. Headquartered in Melbourne, it operates predominantly in Australia and internationally, offering products like Xercise, MedMovie, and iMIX, which cater to medical imaging, patient engagement, and imaging data management. Key services include imaging software and related support.
Market Cap
A$17.4B
Shares on Issue
N/A
Price Chart
AI Analysis
Pro Medicus Limited currently holds a strong position in the Australian health care tech sector, with a market capitalization of A$17.4B as of recent data. Recent performance has been robust, driven by the demand for digital health solutions. Key metrics include consistent revenue growth and a strong balance sheet. The company's long-term contracts with major health providers underpin its stability.
Looking ahead, PME's growth outlook is positive, fueled by the global shift towards integrated digital health platforms. Upcoming catalysts may include new product launches, potential acquisitions to expand its suite of services, and further international expansion, particularly into the APAC region. Strategic direction is likely focused on innovating its software offerings to meet evolving healthcare tech needs.
Bull Case
- • Successful expansion of Xercise and MedMovie into the U.S. and European markets could significantly boost revenue.
- • Continued innovation in AI-powered imaging solutions could lead to market share gains.
- • Potential for strategic acquisitions to enhance its product portfolio and reach.
Bear Case
- • Intense competition from global health tech giants could limit market share expansion.
- • Regulatory challenges in new markets (e.g., U.S., EU) might slow international growth plans.
- • Dependence on long-term contracts poses risks if major clients opt not to renew.
Recent Announcements
PME HY Results release date and webcast briefing
Notification regarding unquoted securities - PME
Notification of cessation of securities - PME
Notification regarding unquoted securities - PME
Notification regarding unquoted securities - PME
FAQs
What does PME do?
Pro Medicus Limited develops and provides diagnostic imaging software and services, including patient engagement tools and imaging data management solutions, primarily to the healthcare sector.
Is PME a good investment?
PME offers a compelling growth story with its strong market position and growth prospects. However, investors should weigh this against the speculative nature of tech stocks, potential competition, and regulatory risks.
What drives PME's share price?
Key drivers include contract wins/losses, innovation in product offerings, international expansion success, global demand for digital health solutions, and broader tech sector trends.
Key Metrics
Related Stocks
Health Care
CSLCSL Ltd
A$181.24
-27.3% 1Y
CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.
Health Care
PNVPolynovo Ltd
A$0.99
-13.1% 1Y
Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.
Health Care
1ADAdalta Limited
A$0.01
-25.6% 1Y
Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.